Omnicell, Inc. $OMCL Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. cut its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 7.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 592,144 shares of the company's stock after selling 47,397 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 1.26% of Omnicell worth $20,701,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in OMCL. Jacobs Levy Equity Management Inc. purchased a new stake in Omnicell in the first quarter valued at approximately $870,000. Curi RMB Capital LLC raised its position in Omnicell by 2.9% in the first quarter. Curi RMB Capital LLC now owns 92,447 shares of the company's stock valued at $3,232,000 after purchasing an additional 2,617 shares during the period. AQR Capital Management LLC raised its position in Omnicell by 42.1% in the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock valued at $627,000 after purchasing an additional 5,311 shares during the period. Perbak Capital Partners LLP purchased a new stake in shares of Omnicell during the first quarter worth $347,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Omnicell during the first quarter worth $245,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Bank of America boosted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler decreased their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Finally, Wells Fargo & Company upped their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, July 21st. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Price Performance

NASDAQ:OMCL traded down $1.45 during trading hours on Friday, hitting $31.83. The company's stock had a trading volume of 492,448 shares, compared to its average volume of 500,188. The business's 50-day moving average is $30.71 and its two-hundred day moving average is $31.05. The company has a market capitalization of $1.46 billion, a PE ratio of 63.66, a PEG ratio of 7.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to analysts' expectations of $275.57 million. During the same period last year, the company posted $0.51 EPS. The company's revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.